In conclusion, this study substantiates the rationale for a therapeutic design that simultaneously targets multiple cytokines, such as OSM, IL-6, and IL-1β, as these cytokines are strongly correlated with each other in breast cancer. This evidence concerns the gene IL1B and breast cancer.